AI Article Synopsis
- Researchers utilized structure- and ligand-based design methods to create new Na1.7 inhibitors based on piperidyl chromane arylsulfonamide.
- They improved the drug's effectiveness by refining its chemical structure and reducing its breakdown in the body, leading to the identification of a compound called GNE-616 (24).
- GNE-616 demonstrated strong performance in experiments with mice and showed selectivity for specific Na1.7 isoforms, which was further studied through site-directed mutagenesis.
Article Abstract
Using structure- and ligand-based design principles, a novel series of piperidyl chromane arylsulfonamide Na1.7 inhibitors was discovered. Early optimization focused on improvement of potency through refinement of the low energy ligand conformation and mitigation of high in vivo clearance. An in vitro hepatotoxicity hazard was identified and resolved through optimization of lipophilicity and lipophilic ligand efficiency to arrive at GNE-616 (24), a highly potent, metabolically stable, subtype selective inhibitor of Na1.7. Compound 24 showed a robust PK/PD response in a Na1.7-dependent mouse model, and site-directed mutagenesis was used to identify residues critical for the isoform selectivity profile of 24.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1021/acs.jmedchem.9b00141 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!